Arvinas Inc (ARVN)
31.71
-0.24
(-0.75%)
USD |
NASDAQ |
May 10, 13:08
Arvinas Cash from Financing (TTM): 374.80M for March 31, 2024
Cash from Financing (TTM) Chart
Historical Cash from Financing (TTM) Data
Date | Value |
---|---|
March 31, 2024 | 374.80M |
December 31, 2023 | 374.70M |
September 30, 2023 | 40.40M |
June 30, 2023 | 3.70M |
March 31, 2023 | 3.70M |
December 31, 2022 | 4.70M |
September 30, 2022 | 8.10M |
June 30, 2022 | 273.50M |
March 31, 2022 | 276.60M |
December 31, 2021 | 278.60M |
September 30, 2021 | 746.17M |
Date | Value |
---|---|
June 30, 2021 | 510.07M |
March 31, 2021 | 507.75M |
December 31, 2020 | 504.60M |
September 30, 2020 | 141.76M |
June 30, 2020 | 142.02M |
March 31, 2020 | 141.10M |
December 31, 2019 | 139.70M |
September 30, 2019 | 142.18M |
June 30, 2019 | 113.45M |
March 31, 2019 | 113.06M |
December 31, 2018 | 168.06M |
Cash From Financing Definition
Cash flow from financing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall financing activities of the company. A few examples of financing activities include common stock issuance, total dividends paid, and net debt issuance.
Cash from Financing (TTM) Range, Past 5 Years
3.70M
Minimum
Mar 2023
746.17M
Maximum
Sep 2021
236.38M
Average
142.10M
Median
Cash from Financing (TTM) Benchmarks
Pfizer Inc | 23.91B |
Bristol-Myers Squibb Co | 8.278B |
Janux Therapeutics Inc | 59.55M |
Geron Corp | 228.77M |
Verastem Inc | 134.19M |